STENOCARE has completed the move to Nasdaq First North Growth Market Denmark, and today commences trading of its shares with the same symbol "STENO" and ISIN code. The existing +4.000 shareholders has automatically had their STENOCARE shares registered for Nasdaq and they do not need to take any action with their bank and securities accounts.

Thomas Schnegelsberg, CEO of STENOCARE comments:

"Today marks an important milestone for our company. We are fortunate to have +4.000 shareholders, and with the move to Nasdaq we look forward to welcoming even more shareholders. Seeing our company logo on the Nasdaq building on Times Square in New York is a fantastic feeling, and is a beacon for our ambition to become a leading European brand for medical cannabis"

Certified Adviser

Keswick Global AG, Reg. FN 332389 h, Hoffingergasse 16/1/6, 1120 Vienna, Austria, telephone number +43 (1) 533 88 90 0.

For additional information regarding STENOCARE, please contact:

Thomas Skovlund Schnegelsberg, CEO

Phone: +45 31770060

E-mail: presse@stenocare.com

About STENOCARE A/S

STENOCARE A/S was founded in 2017 with the purpose of supplying medical cannabis to patients in Denmark and internationally. The company was first to receive the Danish Medicines Agency's permission to import, distribute as well as cultivate and produce medical cannabis. The company offers medical cannabis oil that complies with the strict Danish regulatory requirements. STENOCARE is building a state-of-the-art production facility for the cultivation and production of medical cannabis at the company’s premises in Jutland, Denmark.